EP3906025A4 - Topical formulations having cannabinoid - Google Patents
Topical formulations having cannabinoid Download PDFInfo
- Publication number
- EP3906025A4 EP3906025A4 EP20736215.3A EP20736215A EP3906025A4 EP 3906025 A4 EP3906025 A4 EP 3906025A4 EP 20736215 A EP20736215 A EP 20736215A EP 3906025 A4 EP3906025 A4 EP 3906025A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- cannabinoid
- topical formulations
- topical
- formulations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22002—Papain (3.4.22.2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/04—Skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962788494P | 2019-01-04 | 2019-01-04 | |
PCT/US2020/012187 WO2020142692A1 (en) | 2019-01-04 | 2020-01-03 | Topical formulations having cannabinoid |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3906025A1 EP3906025A1 (en) | 2021-11-10 |
EP3906025A4 true EP3906025A4 (en) | 2022-09-21 |
Family
ID=71406979
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20736215.3A Withdrawn EP3906025A4 (en) | 2019-01-04 | 2020-01-03 | Topical formulations having cannabinoid |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP3906025A4 (en) |
WO (1) | WO2020142692A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
US20220047541A1 (en) * | 2020-08-17 | 2022-02-17 | Pike Therapeutics, Inc. | Pharmaceutical compositions and methods for treating parkinson's disease |
WO2022217147A1 (en) * | 2021-04-09 | 2022-10-13 | Rosenfeld Mark J | Methods for improving cutaneous permeation of cannabinoids and fatty acid amides |
CN113244410A (en) * | 2021-05-28 | 2021-08-13 | 哈尔滨工业大学 | Preparation method of clathrate compound based on porous starch and used for increasing cannabidiol water solubility |
PL443690A1 (en) * | 2023-02-05 | 2024-08-12 | Rodakowska Ewelina | Composition of plant-derived compounds, method of its preparation and use for medicinal purposes |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015200049A1 (en) * | 2014-06-26 | 2015-12-30 | Island Breeze Systems Ca, Llc | Mdi related products and methods of use |
US20160309774A1 (en) * | 2015-04-27 | 2016-10-27 | Michael D. Wand | Terpene carrier |
WO2018023164A1 (en) * | 2016-08-03 | 2018-02-08 | Zelda Therapeutics Operations Pty Ltd | Cannabis composition |
WO2018236957A1 (en) * | 2017-06-20 | 2018-12-27 | Nexien Biopharma, Inc. | Method and compositions for treating restless legs syndrome |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9375417B2 (en) * | 2014-12-04 | 2016-06-28 | Mary's Medicinals LLC | Transdermal cannabinoid formulations |
SG11201809688RA (en) * | 2016-05-04 | 2018-11-29 | Inmed Pharmaceuticals Inc | Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders |
US20170348276A1 (en) * | 2016-06-02 | 2017-12-07 | Acerus Pharmaceutical Corporation | Nasal cannabidiol compositions |
-
2020
- 2020-01-03 WO PCT/US2020/012187 patent/WO2020142692A1/en unknown
- 2020-01-03 EP EP20736215.3A patent/EP3906025A4/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015200049A1 (en) * | 2014-06-26 | 2015-12-30 | Island Breeze Systems Ca, Llc | Mdi related products and methods of use |
US20160309774A1 (en) * | 2015-04-27 | 2016-10-27 | Michael D. Wand | Terpene carrier |
WO2018023164A1 (en) * | 2016-08-03 | 2018-02-08 | Zelda Therapeutics Operations Pty Ltd | Cannabis composition |
WO2018236957A1 (en) * | 2017-06-20 | 2018-12-27 | Nexien Biopharma, Inc. | Method and compositions for treating restless legs syndrome |
Non-Patent Citations (3)
Title |
---|
CHERNIAKOV IRINA ET AL: "Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 266, 8 September 2017 (2017-09-08), pages 1 - 7, XP085292686, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2017.09.011 * |
P K LAKSHMI ET AL: "OILS AS PENETRATION ENHANCERS FOR IMPROVED TRANSDERMAL DRUG DELIVERY: A REVIEW", INTERNATIONAL RESEARCH JOURNAL OF PHARMACY, vol. 8, no. 4, 30 May 2017 (2017-05-30), pages 9 - 17, XP055949663, Retrieved from the Internet <URL:http://www.irjponline.com/admin/php/uploads/2645_pdf.pdf> DOI: 10.7897/2230-8407.080440 * |
See also references of WO2020142692A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP3906025A1 (en) | 2021-11-10 |
WO2020142692A1 (en) | 2020-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3735240A4 (en) | Solid self-emuslifying cannabinoid compositions | |
EP3703672A4 (en) | Cannabinoid formulations | |
GB2584341B (en) | Cannabinoid formulations | |
EP3746086A4 (en) | Topical formulations comprising tofacitinib | |
EP3906025A4 (en) | Topical formulations having cannabinoid | |
EP3994114A4 (en) | Cannabinoid derivatives | |
EP3615079A4 (en) | Stable cannabinoid formulations | |
EP3997098A4 (en) | Cannabinoid derivatives | |
EP3746043A4 (en) | Topical compositions | |
EP3946315A4 (en) | Cannabinoid compositions and use thereof | |
EP4121020A4 (en) | Cannabinoid compositions | |
EP4038058A4 (en) | Cannabinoid derivatives | |
EP4037676A4 (en) | Cannabinoid derivatives | |
EP3999490A4 (en) | Cannabinoid derivatives | |
EP3817750A4 (en) | Cannabidiol combination compositions | |
EP3876907A4 (en) | Suppository formulations having cannabinoid | |
EP4034100A4 (en) | Cannabinoid prodrug compounds | |
EP4073033A4 (en) | Cannabinoid derivatives | |
EP4065549A4 (en) | Cannabinoid derivatives | |
EP3997069A4 (en) | Cannabinoid derivatives | |
EP3997095A4 (en) | Cannabinoid derivatives | |
EP3994129A4 (en) | Cannabinoid derivatives | |
EP4007590A4 (en) | Formulations including dihydrohonokiol | |
EP4073053A4 (en) | Cannabinoid derivatives | |
EP4065568A4 (en) | Cannabinoid derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210803 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20220819 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61M 11/00 20060101ALI20220812BHEP Ipc: A61P 17/00 20060101ALI20220812BHEP Ipc: A61P 35/00 20060101ALI20220812BHEP Ipc: A61P 25/00 20060101ALI20220812BHEP Ipc: A61K 38/48 20060101ALI20220812BHEP Ipc: A61K 36/81 20060101ALI20220812BHEP Ipc: A61K 9/12 20060101ALI20220812BHEP Ipc: A61K 9/00 20060101ALI20220812BHEP Ipc: A61K 36/67 20060101ALI20220812BHEP Ipc: A61K 36/185 20060101ALI20220812BHEP Ipc: A61K 31/05 20060101ALI20220812BHEP Ipc: A61K 31/352 20060101AFI20220812BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20230303 |